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background:  Few trials explore safety and efficacy of rivaroxaban in ablation and cardioversion (DCCV) procedures of atrial fibrillation 
(AFIB). We aim to explore the hypothesis that rivaroxaban results in equal outcomes compared to Vitamin K Antagonists (VKA) in these 
procedures.
Methods:  We searched the online databases and conference abstracts till September 2014 for case control studies comparing 
rivaroxaban with VKA in AFIB patients undergoing catheter ablation or DCCV. We report events as Odds ratio using random effects model 
except when event rates were less than 1% we used Peto Odds Ratio.
results:  A total of 7168 AFIB patients in 11 studies were included in this analysis. All trials were observational except two randomized 
trials and a post hoc results of a randomized trial. All were published as full length articles except 4 studies were conference abstracts. 
There were significantly lower stroke events rates with rivaroxaban compared with VKA, 3 (0.13%) vs 19 (0.4%) events, (Peto Odds Ratio 
(POR) 0.33, 95% confidence interval (CI) [0.11, 0.99]; P= 0.05), and lower thrombo-embolic events, 7 (0.29%) vs 26 (0.54%) (POR 0.43, 
95% CI [0.19, 0.98]; P=0.04). Major and minor bleeding were equal, (OR 0.94, 95% CI [0.61, 1.44]; P=0.77) and (OR 0.78,95% CI [0.53, 
1.14]; P=0.19) respectively.
Conclusion:  Use of rivaroxaban in ablation or cardioversion of atrial fibrillation may be associated with decreased risk of stroke and 
thromboembolism with equal bleeding risk when compared to VKA.
